Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 367

1.

Evaluation of an antibody to α4β7 in the control of SIVmac239-nef-stop infection.

Di Mascio M, Lifson JD, Srinivasula S, Kim I, DeGrange P, Keele BF, Belli AJ, Reimann KA, Wang Y, Proschan M, Lane HC, Fauci AS.

Science. 2019 Sep 6;365(6457):1025-1029. doi: 10.1126/science.aav6695.

PMID:
31488688
2.

An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals.

Sneller MC, Clarridge KE, Seamon C, Shi V, Zorawski MD, Justement JS, Blazkova J, Huiting ED, Proschan MA, Mora JR, Shetzline M, Moir S, Lane HC, Chun TW, Fauci AS.

Sci Transl Med. 2019 Sep 11;11(509). pii: eaax3447. doi: 10.1126/scitranslmed.aax3447. Epub 2019 Sep 5.

PMID:
31488581
3.

Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller.

Migueles SA, Chairez C, Lin S, Gavil NV, Rosenthal DM, Pooran M, Natarajan V, Rupert A, Dewar R, Rehman T, Sherman BT, Adelsberger J, Leitman S, Stroncek D, Morse CG, Connors M, Lane HC, Kovacs JA.

JCI Insight. 2019 Aug 15. pii: 130664. doi: 10.1172/jci.insight.130664. [Epub ahead of print]

4.

8-Day Inpatient Directly Observed Therapy for ART Failure: A Tool For Preventing Unnecessary ART Changes and Optimizing Adherence Support.

Winchester NE, Maldarelli F, Mejia Y, Dee N, Dewar R, Laidlaw E, Kuriakose SS, Stoll P, Proschan M, Lane HC, Pau AK.

Clin Infect Dis. 2019 Jul 11. pii: ciz590. doi: 10.1093/cid/ciz590. [Epub ahead of print]

PMID:
31298273
5.

Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.

Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, Sherman BT, Losso MH, Wood R, Paredes R, Molina JM, Helleberg M, Jina N, Kityo CM, Florence E, Polizzotto MN, Neaton JD, Lane HC, Lundgren JD.

J Infect Dis. 2019 Sep 13;220(8):1325-1334. doi: 10.1093/infdis/jiz294.

PMID:
31219150
6.

New filovirus disease classification and nomenclature.

Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA 2nd, Fletcher TE, Fowler RA, Grünewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF, Kapetshi J, Klenk HD, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM 3rd, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclares C, Nanyunja M, Nsio-Mbeta J, O'Dempsey T, Pawęska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, Yoti Z.

Nat Rev Microbiol. 2019 May;17(5):261-263. doi: 10.1038/s41579-019-0187-4. No abstract available.

7.

Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response.

Revell AD, Wang D, Perez-Elias MJ, Wood R, Tempelman H, Clotet B, Reiss P, van Sighem AI, Alvarez-Uria G, Nelson M, Montaner JSG, Lane HC, Larder BA.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):207-215. doi: 10.1097/QAI.0000000000001989.

PMID:
30865186
8.

A Longitudinal Study of Ebola Sequelae in Liberia.

PREVAIL III Study Group, Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, Moses SJ, Johnson KL, Gayedyu-Dennis D, Hensley LE, Higgs ES, Nath A, Tuznik K, Varughese J, Jensen KS, Dighero-Kemp B, Neaton JD, Lane HC, Fallah MP.

N Engl J Med. 2019 Mar 7;380(10):924-934. doi: 10.1056/NEJMoa1805435.

9.

PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.

Bolay FK, Grandits G, Lane HC, Kennedy SB, Johnson MP, Fallah MP, Wilson B, Njoh WS, McNay LA, Hensley LE, Higgs ES.

J Infect Dis. 2019 Apr 19;219(10):1634-1641. doi: 10.1093/infdis/jiy698.

10.

The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection.

Davey RT Jr, Dodd L, Proschan M, Jahrling P, Hensley L, Higgs E, Lane HC.

J Infect Dis. 2018 Nov 22;218(suppl_5):S690-S697. doi: 10.1093/infdis/jiy334.

PMID:
30032267
11.

Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation.

Schreiber-Stainthorp W, Sinharay S, Srinivasula S, Shah S, Wang J, Dodd L, Lane HC, Di Mascio M, Hammoud DA.

J Neuroinflammation. 2018 Jul 14;15(1):207. doi: 10.1186/s12974-018-1244-z.

12.

Total body CD4+ T cell dynamics in treated and untreated SIV infection revealed by in vivo imaging.

Di Mascio M, Srinivasula S, Kim I, Duralde G, St Claire A, DeGrange P, St Claire M, Reimann KA, Gabriel EE, Carrasquillo J, Reba RC, Paik C, Lane HC.

JCI Insight. 2018 Jul 12;3(13). pii: 97880. doi: 10.1172/jci.insight.97880.

13.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.

Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Rehm CA, Pozniak A, Montaner JSG, Lane HC, Larder BA; RDI Data and Study Group .

J Antimicrob Chemother. 2018 Aug 1;73(8):2186-2196. doi: 10.1093/jac/dky179.

14.

Virtual Sprouts: A Virtual Gardening Pilot Intervention Increases Self-Efficacy to Cook and Eat Fruits and Vegetables in Minority Youth.

Bell BM, Martinez L, Gotsis M, Lane HC, Davis JN, Antunez-Castillo L, Ragusa G, Spruijt-Metz D.

Games Health J. 2018 Apr;7(2):127-135. doi: 10.1089/g4h.2017.0102. Epub 2018 Feb 2.

15.

Learner-Adaptive Educational Technology for Simulation in Healthcare: Foundations and Opportunities.

Lineberry M, Dev P, Lane HC, Talbot TB.

Simul Healthc. 2018 Jun;13(3S Suppl 1):S21-S27. doi: 10.1097/SIH.0000000000000274.

PMID:
29346223
16.

Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.

Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, Munderi P, Aho I, Emery S, Babiker A, Phillips A, Lundgren JD, Neaton JD, Lane HC; INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group.

Open Forum Infect Dis. 2017 Nov 28;4(4):ofx262. doi: 10.1093/ofid/ofx262. eCollection 2017 Fall.

17.

IL-7-dependent STAT1 activation limits homeostatic CD4+ T cell expansion.

Le Saout C, Luckey MA, Villarino AV, Smith M, Hasley RB, Myers TG, Imamichi H, Park JH, O'Shea JJ, Lane HC, Catalfamo M.

JCI Insight. 2017 Nov 16;2(22). pii: 96228. doi: 10.1172/jci.insight.96228. eCollection 2017 Nov 16.

18.

CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies.

Srinivasula S, Gabriel E, Kim I, DeGrange P, St Claire A, Mallow C, Donahue RE, Paik C, Lane HC, Di Mascio M.

PLoS One. 2017 Nov 9;12(11):e0187912. doi: 10.1371/journal.pone.0187912. eCollection 2017.

19.

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, Gupta S, Hensley L, Higgs E, Janosko K, Johnson M, Kateh F, Logue J, Marchand J, Monath T, Nason M, Nyenswah T, Roman F, Stavale E, Wolfson J, Neaton JD, Lane HC; PREVAIL I Study Group.

N Engl J Med. 2017 Oct 12;377(15):1438-1447. doi: 10.1056/NEJMoa1614067.

20.

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.

Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, Panuto J, Beasley RL, Perez-Patrigeon S, Suwanpimolkul G, Losso MH, McClure N, Bozzolo DR, Myers C, Holley HP Jr, Hoopes J, Lane HC, Hughes MD, Davey RT; IRC003 Study Team.

Lancet Infect Dis. 2017 Dec;17(12):1255-1265. doi: 10.1016/S1473-3099(17)30476-0. Epub 2017 Sep 22.

21.

STING is an essential mediator of the Ku70-mediated production of IFN-λ1 in response to exogenous DNA.

Sui H, Zhou M, Imamichi H, Jiao X, Sherman BT, Lane HC, Imamichi T.

Sci Signal. 2017 Jul 18;10(488). pii: eaah5054. doi: 10.1126/scisignal.aah5054.

PMID:
28720717
22.

Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.

Brooks KM, Garrett KL, Kuriakose SS, George JM, Balba G, Bailey B, Anderson M, Lane HC, Maldarelli F, Pau AK.

Pharmacotherapy. 2017 Aug;37(8):e82-e89. doi: 10.1002/phar.1960. Epub 2017 Jul 18.

23.

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.

Beigel JH, Tebas P, Elie-Turenne MC, Bajwa E, Bell TE, Cairns CB, Shoham S, Deville JG, Feucht E, Feinberg J, Luke T, Raviprakash K, Danko J, O'Neil D, Metcalf JA, King K, Burgess TH, Aga E, Lane HC, Hughes MD, Davey RT; IRC002 Study Team.

Lancet Respir Med. 2017 Jun;5(6):500-511. doi: 10.1016/S2213-2600(17)30174-1. Epub 2017 May 15. Erratum in: Lancet Respir Med. 2017 Jul;5(7):e26.

24.

Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox.

Sowrirajan B, Saito Y, Poudyal D, Chen Q, Sui H, DeRavin SS, Imamichi H, Sato T, Kuhns DB, Noguchi N, Malech HL, Lane HC, Imamichi T.

Sci Rep. 2017 Feb 27;7:43441. doi: 10.1038/srep43441.

25.

Rapid Recall Ability of Memory T cells is Encoded in their Epigenome.

Barski A, Cuddapah S, Kartashov AV, Liu C, Imamichi H, Yang W, Peng W, Lane HC, Zhao K.

Sci Rep. 2017 Jan 5;7:39785. doi: 10.1038/srep39785.

26.

Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation.

Swaminathan S, Qiu J, Rupert AW, Hu Z, Higgins J, Dewar RL, Stevens R, Rehm CA, Metcalf JA, Sherman BT, Baseler MW, Lane HC, Imamichi T.

PLoS One. 2016 Nov 23;11(11):e0167091. doi: 10.1371/journal.pone.0167091. eCollection 2016.

27.

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).

Gill AL, Green SA, Abdullah S, Le Saout C, Pittaluga S, Chen H, Turnier R, Lifson J, Godin S, Qin J, Sneller MC, Cuillerot JM, Sabzevari H, Lane HC, Catalfamo M.

AIDS. 2016 Oct 23;30(16):2487-2493.

28.

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

PREVAIL II Writing Group; Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D.

N Engl J Med. 2016 Oct 13;375(15):1448-1456.

29.

Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Imamichi H, Dewar RL, Adelsberger JW, Rehm CA, O'Doherty U, Paxinos EE, Fauci AS, Lane HC.

Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8783-8. doi: 10.1073/pnas.1609057113. Epub 2016 Jul 18.

30.

Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa.

Revell A, Khabo P, Ledwaba L, Emery S, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem A, Pozniak A, Montaner J, Lane HC, Larder B.

South Afr J HIV Med. 2016 Jun 30;17(1):450. doi: 10.4102/sajhivmed.v17i1.450. eCollection 2016.

31.

An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group.

J Antimicrob Chemother. 2016 Oct;71(10):2928-37. doi: 10.1093/jac/dkw217. Epub 2016 Jun 20.

32.

Severe Meningoencephalitis in a Case of Ebola Virus Disease: A Case Report.

Chertow DS, Nath A, Suffredini AF, Danner RL, Reich DS, Bishop RJ, Childs RW, Arai AE, Palmore TN, Lane HC, Fauci AS, Davey RT.

Ann Intern Med. 2016 Aug 16;165(4):301-4. doi: 10.7326/M15-3066. Epub 2016 Apr 5. No abstract available.

33.

The pharmacist: An indispensable partner in HIV care.

Pau AK, Lane HC, Masur H.

Am J Health Syst Pharm. 2016 Apr 1;73(7):431. doi: 10.2146/ajhp160077. No abstract available.

PMID:
27001981
34.

Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.

Mikula JM, Manion MM, Maldarelli F, Suarez LM, Norman-Wheeler JF, Ober AG, Dewar RL, Kopp JB, Lane HC, Pau AK.

Antivir Ther. 2016;21(6):553-558. doi: 10.3851/IMP3040. Epub 2016 Mar 8.

35.

Towards Better Precision Medicine: PacBio Single-Molecule Long Reads Resolve the Interpretation of HIV Drug Resistant Mutation Profiles at Explicit Quasispecies (Haplotype) Level.

Huang DW, Raley C, Jiang MK, Zheng X, Liang D, Rehman MT, Highbarger HC, Jiao X, Sherman B, Ma L, Chen X, Skelly T, Troyer J, Stephens R, Imamichi T, Pau A, Lempicki RA, Tran B, Nissley D, Lane HC, Dewar RL.

J Data Mining Genomics Proteomics. 2016 Jan;7(1). pii: 182. Epub 2015 Nov 8.

36.

Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study.

Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT Jr.

J Infect Dis. 2016 Jun 15;213(12):1906-13. doi: 10.1093/infdis/jiw061. Epub 2016 Feb 11.

37.

Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges.

Kennedy SB, Neaton JD, Lane HC, Kieh MW, Massaquoi MB, Touchette NA, Nason MC, Follmann DA, Boley FK, Johnson MP, Larson G, Kateh FN, Nyenswah TG.

Clin Trials. 2016 Feb;13(1):49-56. doi: 10.1177/1740774515621037. Epub 2016 Jan 14.

PMID:
26768572
38.

Conducting clinical trials in outbreak settings: Points to consider.

Lane HC, Marston HD, Fauci AS.

Clin Trials. 2016 Feb;13(1):92-5. doi: 10.1177/1740774515618198. Epub 2016 Jan 14. No abstract available.

39.

Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study.

Donahue RE, Srinivasula S, Uchida N, Kim I, St Claire A, Duralde G, DeGrange P, St Claire M, Reba RC, Bonifacino AC, Krouse AE, Metzger ME, Paik CH, Lane HC, Tisdale JF, Di Mascio M.

Blood. 2015 Dec 10;126(24):2632-41. doi: 10.1182/blood-2015-07-657346. Epub 2015 Oct 22.

40.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.

41.

Serious Games for Health: Features, Challenges, Next Steps.

Blumberg MF, Burke LC, Hodent PC, Evans MA, Lane HC, Schell J.

Games Health J. 2014 Oct;3(5):270-6. doi: 10.1089/g4h.2014.0079.

PMID:
26192481
42.

HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls.

Swaminathan S, Sui H, Adelsberger JW, Chen Q, Sneller M, Migueles SA, Kottilil S, Ober A, Jones S, Rehm CA, Lane HC, Imamichi T.

J AIDS Clin Res. 2014 Jun;5(6). pii: 315.

43.

Activated platelet-T-cell conjugates in peripheral blood of patients with HIV infection: coupling coagulation/inflammation and T cells.

Green SA, Smith M, Hasley RB, Stephany D, Harned A, Nagashima K, Abdullah S, Pittaluga S, Imamichi T, Qin J, Rupert A, Ober A, Lane HC, Catalfamo M.

AIDS. 2015 Jul 17;29(11):1297-308. doi: 10.1097/QAD.0000000000000701.

44.

Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States.

Liddell AM, Davey RT Jr, Mehta AK, Varkey JB, Kraft CS, Tseggay GK, Badidi O, Faust AC, Brown KV, Suffredini AF, Barrett K, Wolcott MJ, Marconi VC, Lyon GM 3rd, Weinstein GL, Weinmeister K, Sutton S, Hazbun M, Albariño CG, Reed Z, Cannon D, Ströher U, Feldman M, Ribner BS, Lane HC, Fauci AS, Uyeki TM.

Ann Intern Med. 2015 Jul 21;163(2):81-90. doi: 10.7326/M15-0530.

45.

State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus.

Jahrling PB, Hensley LE, Barrett K, Lane HC, Davey RT.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S84-90. doi: 10.1093/infdis/jiv115. Epub 2015 May 9.

46.

Tuberculosis specific responses following therapy for TB: Impact of HIV co-infection.

Siddiqui S, Sarro Y, Diarra B, Diallo H, Guindo O, Dabitao D, Tall M, Hammond A, Kassambara H, Goita D, Dembele P, Traore B, Hengel R, Nason M, Warfield J, Washington J, Polis M, Diallo S, Dao S, Koita O, Lane HC, Catalfamo M, Tounkara A.

Clin Immunol. 2015 Jul;159(1):1-12. doi: 10.1016/j.clim.2015.04.002. Epub 2015 Apr 15.

PMID:
25889622
47.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

48.

Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, Link CJ Jr, Rubinson L, Ströher U, Wolcott M, Dorman W, Uyeki TM, Feldmann H, Lane HC, Mulligan MJ.

JAMA. 2015 Mar 24-31;313(12):1249-55. doi: 10.1001/jama.2015.1995.

49.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17.

50.

Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies.

Lynfield R, Davey R, Dwyer DE, Losso MH, Wentworth D, Cozzi-Lepri A, Herman-Lamin K, Cholewinska G, David D, Kuetter S, Ternesgen Z, Uyeki TM, Lane HC, Lundgren J, Neaton JD; INSIGHT Influenza Study Group.

PLoS One. 2014 Jul 8;9(7):e101785. doi: 10.1371/journal.pone.0101785. eCollection 2014.

Supplemental Content

Support Center